« Return to News | Awards & Advancement

Peter Bendel and Eran Toledo join Aspect Imaging

Tuesday, February 28, 2012 06:00 AM

Aspect Imaging, a developer of high-performance compact MRI imaging systems, has made two executive appointments:

Peter Bendel, Ph.D., as chief technology officer, will lead Aspect Imaging's platform technology initiatives and continue to create new technology opportunities. He will continue his role on Aspect Imaging's scientific advisory board. Bendel has 30 years of experience in the MRI field. Previously, he worked at the Weizmann Institute of Science in Israel and in the corporate research laboratory of ExxonMobil. He is author of over 60 scientific papers and has been awarded several patents in the MRI field.

Eran Toledo, Ph.D., as vice president of R&D, is responsible for the day-to-day activities of the 30-person engineering team at Aspect Imaging, including software and sequence development, advanced magnet design and mechanical engineering teams. He will help manage Aspect products across the pre-clinical, clinical and industrial markets. Toledo has over 15 years of experience in the medical device field, most recently as vice president of R&D at BSP, a medical device company focused on cardiology applications.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.